Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses patient outcomes associated with PIK3CA mutations.
Clinical Pearls
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses patient outcomes associated with PIK3CA mutations.
A number of studies have analyzed the outcomes of patients with a PIK3CA mutation.
Preclinical data suggest the PIK3CA mutation may make tumors resistant to trastuzumab.
Trastuzumab-naïve patients with HER2 amplification and a PIK3CA mutation seem to do better than those who do not. Patients with a PIK3CA mutation who are treated with trastuzumab seem to do worse.
Patients with a PIK3CA mutation have a lower chance of having a pathologic complete response.
